Condition
Relapsed Small Lymphocytic Lymphoma
Total Trials
4
Recruiting
0
Active
0
Completed
2
Success Rate
66.7%-20% vs avg
Key Insights
Highlights
Success Rate
67% trial completion
Clinical Risk Assessment
Based on trial outcomes
High Risk
Score: 62/100
Termination Rate
25.0%
1 terminated out of 4 trials
Success Rate
66.7%
-19.9% vs benchmark
Late-Stage Pipeline
0%
0 trials in Phase 3/4
Results Transparency
100%
2 of 2 completed with results
Key Signals
2 with results67% success
Data Visualizations
Phase Distribution
4Total
P 1 (2)
P 2 (2)
Trial Status
Completed2
Terminated1
Withdrawn1
Trial Success Rate
66.7%
Benchmark: 86.6%
Based on 2 completed trials
Clinical Trials (4)
Showing 4 of 4 trials
NCT05828589Phase 1Terminated
A Study of BGB-21447, a Bcl-2 Inhibitor, in Mature B-Cell Malignancies
NCT04191187Phase 2Completed
Reduced Intensity Flu/Mel/TBI Conditioning for HAPLO HCT Patients With Hematologic Malignancies
NCT02722668Phase 2Completed
UCB Transplant for Hematological Diseases Using a Non Myeloablative Prep
NCT03639324Phase 1Withdrawn
Rituximab, Idelalisib, and Venetoclax in Relapsed/Refractory CLL/SLL
Showing all 4 trials